Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Weinstein

Showing results (391-400 of 404) with videos related to

Pageof 41
Sort By:
Chemistry (Weinheim an Der Bergstrasse, Germany)|October 16, 2020
Characterizing Polyoxovanadate-Alkoxide Clusters Using Vanadium K-Edge X-Ray Absorption SpectroscopyRachel L Meyer, Samuel M Greer, Anastasia V Blake, et al.
Journal of the American Academy of Dermatology|July 1, 1997
Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effectG D Weinstein, G G Krueger, N J Lowe, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
Journal of the American Academy of Dermatology|October 20, 1998
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasisM G Lebwohl, D L Breneman, B S Goffe, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|December 29, 2019
Measuring Cigarette Smoking Risk PerceptionsAnnette R Kaufman, Jenny E Twesten, Jerry Suls, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
Nature Medicine|February 5, 2025
First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophyGenís Prat-Ortega, Scott Ensel, Serena Donadio, et al.
Surgical Oncology|November 27, 2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancerJames V Pellicane, Peter D Beitsch, David T Rock, et al.
Journal of the American Academy of Dermatology|June 19, 1998
Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenailM R Ling, L J Swinyer, M T Jarratt, et al.
Pageof 41

Showing results (391-400 of 404) with videos related to

Sort By:
Pageof 41
Chemistry (Weinheim an Der Bergstrasse, Germany)|October 16, 2020
Characterizing Polyoxovanadate-Alkoxide Clusters Using Vanadium K-Edge X-Ray Absorption SpectroscopyRachel L Meyer, Samuel M Greer, Anastasia V Blake, et al.
Journal of the American Academy of Dermatology|July 1, 1997
Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effectG D Weinstein, G G Krueger, N J Lowe, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
Journal of the American Academy of Dermatology|October 20, 1998
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasisM G Lebwohl, D L Breneman, B S Goffe, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|December 29, 2019
Measuring Cigarette Smoking Risk PerceptionsAnnette R Kaufman, Jenny E Twesten, Jerry Suls, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
Nature Medicine|February 5, 2025
First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophyGenís Prat-Ortega, Scott Ensel, Serena Donadio, et al.
Surgical Oncology|November 27, 2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancerJames V Pellicane, Peter D Beitsch, David T Rock, et al.
Journal of the American Academy of Dermatology|June 19, 1998
Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenailM R Ling, L J Swinyer, M T Jarratt, et al.
Pageof 41